### 66. highlights that a framework for compulsory licensing is provided for under the existing agreement on trade-related aspects of intellectual property rights , enabling governments to supply their citizens with generic versions of patented treatments either through domestic production or foreign imports; ### 66. highlights that a framework for compulsory licensing is provided for under the existing agreement on trade-related aspects of intellectual property rights , enabling governments to supply their citizens with generic versions of patented treatments either through domestic production or foreign imports; deplores the fact that the covid-19 vaccines were not covered by this framework and hopes that such an oversight will not happen again;


### 66. highlights that a framework for compulsory licensing is provided for under the existing agreement on trade-related aspects of intellectual property rights , enabling governments to supply their citizens with generic versions of patented treatments either through domestic production or foreign imports; ### 66. highlights that a framework for compulsory licensing is provided for under the existing agreement on trade-related aspects of intellectual property rights , but that its practical use is hindered by regulatory data protection , trade secrets and restrictions in import and export of components and finished products produced under a compulsory license;


### 67. acknowledges that the eu is a major exporter of vaccines in the world and that it contributed to the worldwide solidarity efforts with the donation of 500 million doses of vaccines; ### 67. acknowledges companies based in the eu is are major exporters of vaccines in the world and that eu institutions have contributed to the worldwide solidarity efforts with the donation of 500 million doses of vaccines;


### 67. acknowledges that the eu is a major exporter of vaccines in the world and that it contributed to the worldwide solidarity efforts with the donation of 500 million doses of vaccines; ### 67. acknowledges that the eu is a major exporter of vaccines in the world and that it contributed to the worldwide efforts with the donation of 500 million doses of vaccines;


### 68. believes that the eu needed a common approach for vaccine procurement in order to avoid competition among member states and the undermining of the european project; believes that the exclusivity in the negotiations of vaccines and the early engagement from the member states were successful points in this process; ### 68. believes that the eu needed no common approach whatsoever for vaccine procurement; believes that the exclusivity in the negotiations of vaccines , unfair contract terms that favoured manufacturers to the detriment of the member states , and the lack of transparency around the contracts , designed to shield the manufacturers’ commercial interests , not to mention the lack of transparency surrounding the text messages between the president of the commission and ceo of pfizer , constituted a flagrant breach of trust and laid bare the shortcomings in and utter inadequacy of this process;


### 68. believes that the eu needed a common approach for vaccine procurement in order to avoid competition among member states and the undermining of the european project; believes that the exclusivity in the negotiations of vaccines and the early engagement from the member states were successful points in this process; ### 68. believes that the eu needed a common approach for vaccine procurement in order to maximize member states bargaining power; early engagement from the member states were successful points in this process; denounces the lack of transparency in negotiations;


### 68. believes that the eu needed a common approach for vaccine procurement in order to avoid competition among member states and the undermining of the european project; believes that the exclusivity in the negotiations of vaccines and the early engagement from the member states were successful points in this process; ### 68. believes that the eu needed a common approach for vaccine procurement in order to eliminate competition among member states ; believes that the exclusivity in the negotiations of vaccines and the early engagement from the member states were successful points in this process; condemns the lack of transparency in the negotiations ;


### 69. takes the view that joint procurement procedures could provide the eu and its member states with more flexibility according to their needs , whereas negotiations for the advanced purchase agreements were beneficial at a time when the development of vaccines was risky and production lines were prepared without knowing which vaccine would actually succeed or whether the vaccines would actually be approved; ### deleted


### 70. stresses the importance of new joint eu voluntary public-procurement contracts by the commission and the member states , especially for , but not limited to , emergency medicines and unmet therapeutic needs , to improve their affordability and access to them at eu level; calls for such practices to be explored in areas such as rare diseases and cancer through clearly outlined milestones , objectives and commitments agreed on by all parties involved; highlights the need to ensure high levels of transparency in these initiatives and to apply lessons learned from the joint procurement of covid-19 products; stresses that joint procurement must not risk having a negative impact on supply flows by increasing the risk of shortages in the eu; ### 70. stresses the importance of new joint eu voluntary public-procurement contracts by the commission and the member states , especially for , but not limited to; health emergencies highlights the need to ensure high levels of transparency in these initiatives and to apply lessons learned from the joint procurement of covid-19 products; stresses that joint procurement must not risk having a negative impact on supply flows by increasing the risk of shortages in the eu; calls for joint procurement initiatives to diversify the number of suppliers which can help ensuring supply security;


### 70. stresses the importance of new joint eu voluntary public-procurement contracts by the commission and the member states , especially for , but not limited to , emergency medicines and unmet therapeutic needs , to improve their affordability and access to them at eu level; calls for such practices to be explored in areas such as rare diseases and cancer through clearly outlined milestones , objectives and commitments agreed on by all parties involved; highlights the need to ensure high levels of transparency in these initiatives and to apply lessons learned from the joint procurement of covid-19 products; stresses that joint procurement must not risk having a negative impact on supply flows by increasing the risk of shortages in the eu; ### 70. notes the option of new joint eu voluntary public-procurement contracts by the commission and the member states , especially for , but not limited to , emergency medicines and unmet therapeutic needs , to improve their affordability and access to them at eu level; calls for such practices to be explored in areas such as rare diseases and cancer through clearly outlined milestones , objectives and commitments agreed on by all parties involved; highlights the need to ensure high levels of transparency in these initiatives and to apply lessons learned from the mistakes that were made through the joint procurement of covid-19 products; stresses that joint procurement must not risk having a negative impact on supply flows by increasing the risk of shortages in the eu;


### 71. welcomes the reference in the pharmaceutical strategy for europe to the fact that actions in the area of public procurement can foster competition and improve access to medicines; urges the commission , in the context of directive 2014/24/eu23 , to swiftly propose guidelines for the member states , notably on how to best implement the most economically advantageous tender criteria , looking beyond solely the lowest price criteria; emphasises that security of supply is an essential factor and must be used as a qualitative criterion in connection with the awarding of public pharmacy contracts and calls for tendering for the supply of medicines; emphasises the importance of diversified supplies and sustainable procurement practices for pharmaceuticals; proposes that investments in the manufacture of active ingredients and medicinal end products in the eu should also be retained as an essential criterion , as well as the number and location of production sites , the reliability of supply , the reinvestment of profits into r&d and the application of social , environmental , ethical and quality standards; ### 71. welcomes the reference in the pharmaceutical strategy for europe to the fact that actions in the area of public procurement can foster competition and improve access to medicines; urges the commission , in the context of directive 2014/24/eu23 , to swiftly propose guidelines for the member states , notably on how to best implement the most economically advantageous tender criteria , looking beyond solely the lowest price criteria; emphasises that security of supply is an essential factor and must be used as a qualitative criterion in connection with the awarding of public pharmacy contracts and calls for tendering for the supply of medicines; emphasises the importance of diversified supplies and sustainable procurement practices for pharmaceuticals; proposes that investments in the manufacture of active ingredients and medicinal end products in the eu should also be retained as an essential criterion , as well as the number and location of production sites , the reliability of supply , a sharing of the profits with the public sector and their reinvestment into improving and bolstering public health services , and the application of social , environmental , ethical and quality standards;


### 71. welcomes the reference in the pharmaceutical strategy for europe to the fact that actions in the area of public procurement can foster competition and improve access to medicines; urges the commission , in the context of directive 2014/24/eu23 , to swiftly propose guidelines for the member states , notably on how to best implement the most economically advantageous tender criteria , looking beyond solely the lowest price criteria; emphasises that security of supply is an essential factor and must be used as a qualitative criterion in connection with the awarding of public pharmacy contracts and calls for tendering for the supply of medicines; emphasises the importance of diversified supplies and sustainable procurement practices for pharmaceuticals;proposes that investments in the manufacture of active ingredients and medicinal end products in the eu should also be retained as an essential criterion , as well asthe number and location of production sites , the reliability of supply , the reinvestment of profits into r&d and the application of social , environmental , ethical and quality standards; ### 71. welcomes the reference in the pharmaceutical strategy for europe to the fact that actions in the area of public procurement can foster competition and improve access to medicines; urges the commission , in the context of directive 2014/24/eu23 , to swiftly propose guidelines for the member states , notably on how to best implement the most economically advantageous tender criteria , looking beyond solely the lowest price criteria; emphasises that security of supply is an essential factor and must be used as a qualitative criterion in connection with the awarding of public pharmacy contracts and calls for tendering for the supply of medicines; emphasises the importance of diversified supplies and sustainable procurement practices for pharmaceuticals in the eu and globally ,proposes that investments are binded to conditionalities including requirements forthe number and location of production sites , the reliability of supply , the reinvestment of profits into r&d , open science , the sharing of data and research resultsand the application of social , environmental , ethical and quality standards;


### 72. highlights the lack of transparency in the joint procurement agreements negotiated with companies , which was justified by respect for the right to confidentiality; stresses that transparency in the work of the eu institutions is of the utmost importance , especially under the conditions of the unprecedented pandemic crisis; ### 72. highlights the lack of transparency in the joint procurement agreements negotiated with companies , which was motivated by respect for the manufacturers’ commercial interests; stresses that the right to transparency of the eu institutions is recognised as a fundamental right of eu citizens that takes precedence over the need to respect private business interests , and may not be suspended in order to satisfy an overriding public interest such as public health; underscores that safeguarding transparency is therefore of the utmost importance , especially under the conditions of the past pandemic crisis;


### 72. highlights the lack of transparency in the joint procurement agreements negotiated with companies , which was justified by respect for the right to confidentiality; stresses that transparency in the work of the eu institutions is of the utmost importance , especially under the conditions of the unprecedented pandemic crisis; ### 72. highlights the lack of transparency in the joint procurement agreements negotiated with companies; stresses that transparency in the work of the eu institutions is of the utmost importance , especially under the conditions of the unprecedented pandemic crisis; highlights that the european parliament resolution on eu transparency in the development , purchase and distribution of covid-19 vaccines (2021/2678(rsp)); calls on the commission to publish nonredacted versions of the purchase agreements entered into without further delay;


### 73. observes that the causes of long covid are still scientifically uncertain , as are the specifics of what it includes and its long-term impact; highlights that the eu needs a strategic approach in order to address long covid , focusing on increasing research , training and primary care awareness; ### 73. observes that the existence and ultimate causes of what is known as ‘long covid’ are still scientifically uncertain , as are the specifics of its supposed symptoms and long-term impact; highlights that the eu needs to adopt a rigorous scientific approach in order to assess long covid , focusing on the transparency and plurality of research and establishing , in particular , that patients exhibiting the supposed symptoms of long covid had indeed clearly contracted the virus and that no other possible causes or related factors were involved , such as vaccines or medicines taken by the patient; expects that attention and awareness-raising efforts should equally be devoted to the myriad adverse effects of covid vaccines , placing particular emphasis on the most serious and debilitating conditions such as heart inflammations , neurological and cardiovascular disorders , and disruptions to the reproductive and endocrine systems , while also providing for procedures on early diagnosis and treatment to combat these ill-effects and carrying out thorough post-mortem examinations of all suspected vaccine-related deaths;


### 74. stresses that the pandemic had consequences for the health of patients with communicable diseases (cds) and non-communicable diseases (ncds) linked to delays and disruptions in diagnostics and treatments , particularly for hiv , hepatitis , cancer and rare diseases , with a massive decrease in screenings for breast and colorectal cancer; ### 74. stresses that the health strategy adopted in response to the pandemic had consequences for the health of patients with communicable diseases (cds) and non-communicable diseases (ncds) linked to delays and disruptions in diagnostics and treatments , particularly for hiv , hepatitis , cancer and rare diseases , with a massive decrease in screenings for breast and colorectal cancer;


### 75. observes that the disruptions in cancer screenings , along with other early detection services , have raised serious concerns about long-term consequences , as postponed diagnoses inevitably result in cancer being diagnosed at a later stage , making treatment more complex and costly , and reducing survival probabilities24; ### 75. observes that the disruptions in cancer screenings , along with other early detection services , have raised serious concerns about long-term consequences , as postponed diagnoses inevitably result in cancer being diagnosed at a later stage , making treatment more complex and costly , and reducing survival probabilities24; notes with concern that various scientific studies have highlighted an emerging incidence of highly aggressive and fast-developing tumours among vaccinated individuals as a result of a weakened immune system , particularly for those who received booster shots;


### 78. highlights the fact that scientifically recognised , integrative medicine approved by public health authorities can bring benefits to patients in relation to the parallel effects of several diseases , such as cancer , and their treatment; stresses the importance of developing a holistic , integrative and patient-centric approach and of encouraging , where appropriate , the complementary use of these therapies under the supervision of healthcare professionals; ### 78. highlights the fact that scientifically recognised , integrative medicine can bring benefits to patients in relation to the parallel effects of several diseases , such as cancer , and their treatment; stresses the importance of developing a holistic , integrative and patient-centric approach and of encouraging , where appropriate , the complementary use of these therapies under the supervision of healthcare professionals;


### 79. recognises that restrictions and lockdowns led to a rise in mental health issues , particularly for youth; underlines , therefore , the importance of introducing such limiting measures as a last resort; calls for support for eu governments’ actions on mental health with a focus on youth and children , while taking into account the limitations of eu competence in this area; ### 79. recognises that restrictions and lockdowns led to a rise in mental health issues , particularly for youth; underlines , therefore , the importance of introducing such limiting measures as a last resort; notes that health care , care workers and informal carers mental health have been disproportionately affected during the covid-19 pandemics; calls for support for eu governments’ actions on mental health with a focus on youth and children , while taking into account the limitations of eu competence in this area;


### 79. recognises that restrictions and lockdowns led to a rise in mental health issues , particularly for youth; underlines , therefore , the importance of introducing such limiting measures as a last resort; calls for support for eu governments’ actions on mental health with a focus on youth and children , while taking into account the limitations of eu competence in this area; ### 79. recognises that restrictions and lockdowns led to a rise in mental health issues and attempted suicide , particularly among young people; underlines , therefore , that such measures should be avoided , as they have been shown to be ineffective and inordinate when it comes to protecting the most vulnerable people from infection; calls for support for eu governments’ actions on mental health with a focus on youth and children , while taking into account the limitations of eu competence in this area;


### 80. regrets that routine vaccination suffered from setbacks; acknowledges the importance of carrying on and improving these activities to avoid outbreaks of other vaccine-preventable diseases; ### deleted


### 80. regrets that routine vaccination suffered from setbacks; acknowledges the importance of carrying on and improving these activities to avoid outbreaks of other vaccine-preventable diseases; ### 80. regrets that routine vaccination campaigns suffered from setbacks; acknowledges the importance of carrying on and improving these activities to avoid outbreaks of other vaccine-preventable diseases;


### 81. insists that covid-19 and other recent epidemics and pandemics have made it unmistakably clear that human , animal , plant and environmental health cannot be dealt with separately , but need to be addressed in a ‘one health’ approach; highlights that their interdependencies need to be better acknowledged and require intersectional work using a multi-sectoral , transdisciplinary and integrated approach; recalls that 75% of human infectious diseases are zoonotic and that the threat of increasing antimicrobial resistance is one of the leading causes of death worldwide; ### 81. emphasises that , notwithstanding how the sars-cov-2 virus came about , as yet unconfirmed but probably as a result of a laboratory leak , some recent epidemics have demonstrated a correlation of sorts between human , animal , plant and environmental health , which makes it expedient to take a holistic approach to dealing with this issue; highlights that their interdependencies need to be better acknowledged and require intersectional work using a multi-sectoral , transdisciplinary and integrated approach; recalls that 75% of human infectious diseases are zoonotic and that animal diseases pose a threat to the food security and agricultural economy of europe’s territories;


### 82. underline that mainstreaming one health means better able to prevent , predict , prepare for , detect and respond to global health threats at both global and eu level; recommends that the one health approach be designed and implemented through public policies , legislation and research with the engagement of multiple sectors; ### deleted


### 83. encourages the eu and member states to implement the european health union package , developing a permanent agenda for health and looking at healthcare as an investment; calls for basic health services to be strengthened , as a way of improving the general state of health of the population; ### 83. encourages the member states to strengthen basic health services in an effort to improve the general state of health of the population , making use of eu support and funding , where available;


### 83. encourages the eu and member states to implement the european health union package , developing a permanent agenda for health and looking at healthcare as an investment; calls for basic health services to be strengthened , as a way of improving the general state of health of the population; ### 83. encourages the eu and member states to implement the european health union package , developing a permanent agenda for health and looking at public healthcare as an investment; calls for basic health services to be strengthened , as a way of improving the general state of health of the population;


### 84. highlights the need to ensure the performance of epidemiological surveillance at eu level and the availability and interoperability of information systems , new tools and research to strengthen interdisciplinary research and human and social sciences as regards the impact of pandemics and non-pharmaceutical measures; ### 84. highlights the need to ensure the performance of proper epidemiological surveillance at eu level and the availability and interoperability of information systems;


### 86. urges the further digitalisation of administrative services and , wherever appropriate and feasible , the use of online healthcare services; ### deleted


### 176. calls , in this regard , for the eu and member states to boost funding for eu research on children in general and children’s data; ### deleted


### 177. recommends that , in future pandemics , schools and other education facilities should remain open , and education policy should be part of an emergency response strategy; ### 177. recommends that , in any future pandemics or similar emergencies , schools and other education facilities should remain open , and education policy should be part of an emergency response strategy;


### 177. recommends that , in future pandemics , schools and other education facilities should remain open , and education policy should be part of an emergency response strategy; ### 177. recommends that , in future pandemics , schools and other education facilities should be considered to remain open , and education policy should be part of an emergency response strategy;


### 182. calls for the eu and member states to invest and develop online tools and digitally empower older people , support online healthcare services and institutions financially and to develop support measures for caregivers; ### deleted


### 182. calls for the eu and member states to invest and develop online tools and digitally empower older people , support online healthcare services and institutions financially and to develop support measures for caregivers; ### 182. calls for the eu and member states to invest and develop online tools and digitally empower older people , support online healthcare services and institutions financially and to develop support measures for caregivers as well informal carers and homecare providers;


### 184. recommends that the eu and member states invest in a health and care plan for the growing elderly population; ### 184. recommends that the eu and member states ensure the right to long-term care is integrated in their social protection systems and to invest in a health and care plan for meeting the needs of the growing elderly population in a socially-just manner;


### 184. recommends that the eu and member states invest in a health and care plan for the growing elderly population; ### 184. recommends that the eu and member states invest in a health and care plan for the growing elderly population , including the residential care facilities;


### 184. recommends that the eu and member states invest in a health and care plan for the growing elderly population; ### 184. recommends that the eu and member states invest for the health and care of the growing elderly population;


### 185. recommends that member states should carefully evaluate the risk-benefit of the restrictions on physical activity before implementing them; considers that during a health crisis , governments should provide guidance and encourage better diets , physical activity for people with special focus on the vulnerable and disadvantaged groups , in order to increase the resilience of populations in member states in the event of a future pandemic; ### 185. recommends that member states should carefully evaluate the risk-benefit of the restrictions on physical activity before implementing them and should not adopt restrictions on physical activity outside; considers that during a health crisis , governments should provide guidance and encourage better diets , physical activity for people with special focus on the vulnerable and disadvantaged groups , in order to increase the resilience of populations in member states in the event of a future pandemic;


### 186. calls for the eu and member states to invest in a disability-inclusive process of preparedness , to prevent the devastating impacts of future crises; ### 186. calls for the eu and member states to invest in a disability-inclusive process of preparedness , to prevent the devastating impacts of any future crises;


### 187. notes that in spite of massive growth in the trade of medical products , there have been considerable inefficiencies in access to personal protection equipment; ### 187. notes that in spite of massive growth in the trade of medical products , there have been considerable inefficiencies in access to personal protection equipment; treatments , vaccines and diagnostics , deplores export controls on health goods placed in the early stages of the pandemic in eu and globally;


### 188. notes that it is the governments’ responsibility to facilitate the distribution of medical products and that the wto’s role in this regard is to implement international trade facilitation , to promote international regulatory cooperation in order to boost goods imports and to reduce export bans or restrictions which are detrimental for access to vaccines; ### 188. notes that it is the governments’ responsibility to facilitate the distribution of medical products and that the wto’s role in this regard is to facilitate international trade through international cooperation;


### 188. notes that it is the governments’ responsibility to facilitate the distribution of medical products and that the wto’s role in this regard is to implement international trade facilitation , to promote international regulatory cooperation in order to boost goods imports and to reduce export bans or restrictions which are detrimental for access to vaccines; ### 188. notes that it is the governments’ responsibility to facilitate the distribution of medical products and that the wto’s role in this regard is to implement international trade facilitation , to promote international regulatory cooperation in order to boost goods imports and to reduce export bans or restrictions which are detrimental for access to drugs;


### 189. notes the eu’s dependency on external sources of personal protection equipment and questions the role of the wto in terms of supply chains in this regard; ### 189. notes the eu’s dependency on external sources of personal protection equipment;


### 190. highlights that tariff and non-tariff barriers have limited access to vaccines , and considers that the wto should take action to ensure the free flow of supply chains and vaccine deliveries , notably as regards export restrictions; ### 190. highlights that multiple factors have limited access to vaccines , and considers that the wto should take action to ensure lifting of intellectually property barriers , the free flow of supply chains and vaccine deliveries , notably as regards export restrictions;


### 190. highlights that tariff and non-tariff barriers have limited access to vaccines , and considers that the wto should take action to ensure the free flow of supply chains and vaccine deliveries , notably as regards export restrictions; ### 190. highlights that tariff and non-tariff barriers have limited access to drugs , and considers that the wto should take action to ensure the free flow of supply chains and deliveries , notably as regards export restrictions;


### 191. calls for the eu to focus on open strategic autonomy supporting supply chain diversification and resilience , with an open , rules-based multilateral trading system at its core to ensure the global availability of medical products and complemented by a ‘strategic supply chain diversification fund’ to actively support our companies; encourages all countries to join the wto’s agreement on trade in pharmaceutical products and urge for its scope to be extended to all pharmaceutical and medicinal products; ### 191. calls for the eu to focus on open strategic autonomy and supporting global diversification and resilience in production and supply , with an open , rules-based multilateral trading system at its core to ensure the global availability of medical products;


### 192. notes that patent protection is a key incentive for companies to invest in innovation and to produce new medicines; notes , at the same time , that the exclusionary effect of patents may lead to limited market supply and reduced access to medicines and pharmaceutical products; stresses that a balance should be struck between encouraging innovation through the exclusionary effect of patents and ensuring access to medicines and protecting public health; ### 192. notes that patent protection is a key incentive for companies to invest in innovation and to produce new medicines; notes , at the same time , that where the public sector invests enormous sums in the research and development of medicines or vaccines , the intellectual property and patent rights cannot be assigned in full to private companies but should be shared with the public institutions; recalls that the exclusionary effect of patents that are not shared may lead to limited market supply and reduced access to medicines and pharmaceutical products; stresses that a balance should be struck between encouraging innovation through the recognition of patent rights and ensuring access to medicines and protecting public health;


### 192. notes that patent protection is a key incentive for companies to invest in innovation and to produce new medicines; notes , at the same time , that the exclusionary effect of patents may lead to limited market supply and reduced access to medicines and pharmaceutical products; stresses that a balance should be struck between encouraging innovation through the exclusionary effect of patents and ensuring access to medicines and protecting public health; ### 192. notes the importance of public and private investments in innovation and to produce medical tools; notes , at the same time , that the exclusionary effect of patents and other forms of ip protections may lead to limited market supply , exorbitant prices and reduced access to medicines and pharmaceutical products; stresses the need to actively encourage access to innovation and protecting public health; highlights the need to ensure that public funding for biomedical r&d includes conditions that contribute to the availability and affordability of end-products;


### 192. notes that patent protection is a key incentive for companies to invest in innovation and to produce new medicines; notes , at the same time , that the exclusionary effect of patents may lead to limited market supply and reduced access to medicines and pharmaceutical products; stresses that a balance should be struck between encouraging innovation through the exclusionary effect of patents and ensuring access to medicines and protecting public health; ### 192. notes that the exclusionary effect of patents leads to limited market supply and reduced access to medicines and pharmaceutical products; stresses that a balance should be struck between encouraging innovation through the exclusionary effect of patents and ensuring access to medicines and protecting public health; highlights the need to ensure that public funding for biomedical r&d includes conditions that contribute to the availability and affordability of end-products and yield public ownership of ip;


### 193. stresses that wto free trade agreements should not focus exclusively on enforcing ip standards in third countries , but should take into account the impact on generic and biosimilar medicines both in the eu and in third countries , as well as ensure coordination of regulatory standards; ### 193. stresses that wto agreements should not focus on enforcing ip standards in third countries , but should take into account the impact on generic and biosimilar medicines both in the eu and in third countries;


### 194. welcomes the fact that the eu and who have been and remain in close cooperation on every aspect of responses to the pandemic; calls for stronger , more coordinated , international cooperation taking a long-term view and with a stronger who at the centre; ### 194. notes the fact that the eu and who have been and remain in close cooperation on every aspect of responses to the pandemic; points to the criticisms regarding the independence and autonomy of the who from pharmaceutical and financial lobbying , in view of the massive private-sector funding supporting its operation and functioning;


### 194. welcomes the fact that the eu and who have been and remain in close cooperation on every aspect of responses to the pandemic; calls for stronger , more coordinated , international cooperation taking a long-term view and with a stronger who at the centre; ### 194. welcomes the fact that the eu and who have been and remain in close cooperation on every aspect of responses to the pandemic; calls for stronger , more coordinated , international cooperation taking a long-term view and with a stronger well-funded and independent who at the centre;


### 195. emphasises that who accompanied countries from the beginning to the end of their vaccine strategy , until the very last steps of delivery; considers , however , that there were delays and uncertainties in supply , especially in 2021 , and that the situation improved only once global supply was largely meeting global demand; ### 195. emphasises that who accompanied and advised countries from the beginning to the end of their vaccine strategy , neglecting both the aspect of early treatment at home , the absence or inadequacy of which led to hundreds of thousands of victims of untreated infection with sars-cov-2 , and the monitoring of hospital treatment protocols , especially in intensive treatments , in which ministerial protocols were adopted that proved to be extremely inadequate and , in some cases , lethal for patients;


### 195. emphasises that who accompanied countries from the beginning to the end of their vaccine strategy , until the very last steps of delivery; considers , however , that there were delays and uncertainties in supply , especially in 2021 , and that the situation improved only once global supply was largely meeting global demand; ### 195. emphasises that who accompanied countries from the beginning to the end of their vaccine strategy , until the very last steps of delivery; considers , however , that there was a lack of supply to low- and middle-income countries , especially in 2021 , and that the situation improved only once global supply was largely meeting global demand;


### 196. underlines the need to place safeguards on re-exports in order to prevent illicit trade and avoid boosting existing markets; recognises that the destination must be an eligible country but that in the event of a humanitarian emergency , an initially non-eligible country may be the destination; ### 196. underlines that it is unacceptable that controls were put on re-exportation and donations in eu advance purchase agreements which hampered global access and donations by eu member states.; placing limitations in the movements of health goods during a pandemic is problematic , limiting the ability of governments to access to such goods is not acceptable under international law;


### 197. considers that a multilateral and globally coordinated response is crucial to building up global resilience against future health crises , and that global mechanisms need to be given more importance; notes in this regard that such mechanisms need to work on their own improvement; ### 197. considers that a measured european and global response , independent of external pressures and free from conflicts of interest , and based on rigorous scientific foundations and on the precautionary principle , is crucial to building up global resilience against future health crises , and that more attention needs to be paid to the risks and impact of the measures selected; notes in this regard that supranational bodies must never replace or override national sovereign bodies but should accompany and advise them when they so request;


### 197. considers that a multilateral and globally coordinated response is crucial to building up global resilience against future health crises , and that global mechanisms need to be given more importance; notes in this regard that such mechanisms need to work on their own improvement; ### 197. considers that a multilateral and globally coordinated response is crucial to building up global resilience against future health crises , and that global mechanisms need to be more accountable and effective; notes in this regard that existing mechanisms need to work on their own improvement;


### 198. underlines that one health should be among the most prominent subjects of discussion within the who , particularly as regards to the animal-human interface; notes that , although the who one health panel already has given recommendations , there is still a need to find ways to implement them; ### deleted


### 198. underlines that one health should be among the most prominent subjects of discussion within the who , particularly as regards to the animal-human interface; notes that , although the who one health panel already has given recommendations , there is still a need to find ways to implement them; ### 198. underlines that one health approach should remain central to the who , particularly as regards to the animal-human interface; and its approach to anti-microbial resistance (amr);notes that , although the who one health panel already has given recommendations , there is still a need to find ways to implement them at the national and regional levels;


### 198. underlines that one health should be among the most prominent subjects of discussion within the who , particularly as regards to the animal-human interface; notes that , although the who one health panel already has given recommendations , there is still a need to find ways to implement them; ### 198. underlines that one health approach should remain central to who particularly as regards to the animal-human interface and its approach to anti-microbial resistance (amr); notes that , although the who one health panel already has given recommendations , there is still a need to find ways to implement them at the national and regional levels;


### 199. demands that the role of parliaments be taken into account in international discussions in order to increase the legitimacy of those discussions; ### 199. demands that national parliaments and the european parliament be involved in international discussions in order to ensure respect for democratic principles and to increase the transparency of and the different positions expressed within those discussions;


### 200. highlights the fact that covid-19 vaccines global access (covax) was key to delivering vaccines to low and middle-income countries given that their facilities and capacities were built on existing ones; notes that most of low and middle-income countries’ doses came from covax; ### 200. highlights the fact that covid-19 vaccines global access (covax) was used to get rid of the stockpiles of vaccines that had expired or had not been sold in europe because of safety issues (such as astrazeneca and janssen) , sending them to low- and middle-income countries given that their facilities and capacities were built on existing ones; notes that most of low- and middle-income countries’ doses therefore came from covax and most of them ended up being thrown away;


### 200. highlights the fact that covid-19 vaccines global access (covax) was key to delivering vaccines to low and middle-income countries given that their facilities and capacities were built on existing ones; notes that most of low and middle-income countries’ doses came from covax; ### 200. highlights the fact that covid-19 vaccines global access (covax) was created with the aim of delivering vaccines to low and middle-income countries but did not live up to expectations , accumulating delays and failing to meet lmic needs; notes that most of low and middle-income countries’ doses had significant lower immunization rates than high-income countries;


### 200. highlights the fact that covid-19 vaccines global access (covax) was key to delivering vaccines to low and middle-income countries given that their facilities and capacities were built on existing ones; notes that most of low and middle-income countries’ doses came from covax; ### 200. highlights the fact that covid-19 vaccines global access (covax) was created with the aim of delivering vaccines to low and middle-income countries but did not live up to expectations , accumulating delays and failing to meet lmic needs; notes that most of low and middle-income countries had significant lower immunization rates than high-income countries;


### 201. recognises that there is considerable effort at the global scale to increase production capacity; welcomes the fact that the eu became a model in that matter and a large investor both in terms of push (before development) and pull (advance purchase agreements) investments , which made it possible to secure enough vaccines; ### deleted


### 201. recognises that there is considerable effort at the global scale to increase production capacity; welcomes the fact that the eu became a model in that matter and a large investor both in terms of push (before development) and pull (advance purchase agreements) investments , which made it possible to secure enough vaccines; ### 201. recognises that there is considerable effort at the global scale to increase production capacity; the eu became a model in that matter and a large investor both in terms of push (before development) and pull (advance purchase agreements) investments , which made it possible to secure an enormous quantity of vaccine doses , far more than necessary , wasting an enormous amount of public money;


### 202. underlines that public-private cooperation during a pandemic emergency is structurally different from cooperation under ‘normal’ circumstances , where the public side provides long-term investment , additional grants or loans and the private side delivers the product; emphasises that in a pandemic situation , where much more risk is involved , public funding plays an even bigger role in the development cycle of the product (vaccine) , in conjunction with advance purchase agreements before regulatory approval; notes that this can work only if global frameworks are well crafted and if there is close coordination between all the actors involved; ### 202. emphasises that in a pandemic situation , where much more urgency and uncertainty are involved , public funding plays an even bigger role in the development cycle of the product (vaccine) , in conjunction with advance purchase agreements before regulatory approval; stresses the importance to attach access and transparency conditions to the public funding particularly in emergencies and pandemics , and comprises public ownership of ip;


### 202. underlines that public-private cooperation during a pandemic emergency is structurally different from cooperation under ‘normal’ circumstances , where the public side provides long-term investment , additional grants or loans and the private side delivers the product; emphasises that in a pandemic situation , where much more risk is involved , public funding plays an even bigger role in the development cycle of the product (vaccine) , in conjunction with advance purchase agreements before regulatory approval; notes that this can work only if global frameworks are well crafted and if there is close coordination between all the actors involved; ### 202. notes the public-private cooperation where the public side provides long-term investment , additional grants or loans and the private side delivers the product; emphasises that in a pandemic situation , where much more urgency and uncertainty are involved , public funding may play an even bigger role in the development cycle of the product (vaccine) , in conjunction with advance purchase agreements before regulatory approval; stresses the importance to attach access and transparency conditions to the public funding particularly in emergencies and pandemics ;


### 202. underlines that public-private cooperation during a pandemic emergency is structurally different from cooperation under ‘normal’ circumstances , where the public side provides long-term investment , additional grants or loans and the private side delivers the product; emphasises that in a pandemic situation , where much more risk is involved , public funding plays an even bigger role in the development cycle of the product (vaccine) , in conjunction with advance purchase agreements before regulatory approval; notes that this can work only if global frameworks are well crafted and if there is close coordination between all the actors involved; ### 202. underlines that public-private cooperation during a pandemic emergency is structurally different from cooperation under ‘normal’ circumstances , where the public side provides long-term investment , additional grants or loans and the private side delivers the product; emphasises that in a pandemic situation , where much more risk is involved , public funding plays an even bigger role in the development cycle of the product , in conjunction with advance purchase agreements before regulatory approval; notes that this can work only if global frameworks are well crafted and if there is close coordination between all the actors involved , and full transparency;


### 203. considers that team europe has proved to be central in terms of solidarity and underlines the eu’s leadership in the global response to the pandemic; ### deleted


### 203. considers that team europe has proved to be central in terms of solidarity and underlines the eu’s leadership in the global response to the pandemic; ### 203. considers that team europe highlights the eu’s role in the global response to the pandemic;


### 204. notes that team europe has played a key role in supporting r&d efforts in africa to address the provision of critical resources and technical support to help african countries respond effectively to the pandemic and build resilience for the future; ### deleted


### 205. notes that the covid-19 task force of the commission’s directorate-general for internal market , industry , entrepreneurship and smes (dg grow) was central to increasing the eu’s strategic autonomy and resilience in the face of the pandemic , by supporting research and innovation , strengthening supply chains , and encouraging greater cooperation and coordination between member states; ### deleted


### 206. considers that safeguarding the unity of the eu single market and the use of its economic and political leverage was made possible by the development of the external dimension of the eu’s operational autonomy , through the eu-wide export authorisation mechanism; ### deleted


### 207. considers that although the level of public funding for r&d was sufficient for the rapid development of vaccines , manufacturing capacities in the eu were scaled up too slowly to match needs; ### deleted


### 207. considers that although the level of public funding for r&d was sufficient for the rapid development of vaccines , manufacturing capacities in the eu were scaled up too slowly to match needs; ### 207. considers that although the level of public funding for r&d was sufficient for the rapid development of vaccines , manufacturing capacities in the eu were scaled up too slowly to match needs; stresses that sharing ip and know-how is necessary to ensure large-scale production and global availability of medical countermeasures;


### 208. considers it essential to ensure the openness of global supply chains to eu manufacturers , by maintaining close cooperation with the eu’s international partners and counterparts and by responsibly responding to protectionist reflexes from said counterparts , such as the america first principle; ### deleted


### 209. asks for tools to be set up allowing the commission to implement reciprocal trade policies when needed (to counter the defence production act , for example) , and thereby maintain an equal balance of power and bargaining abilities; ### deleted


### 210. emphasises that the eu has taken the lead in the global response and solidarity and must continue to play this role; considers that the eu must continue to lead vaccine solidarity around the world and that vaccine solidarity is part of the eu’s one health approach; ### deleted


### 211. underlines that the world is likely to face new epidemics and pandemics in the future and that the eu’s one health approach entails being active in global preparedness , notably regarding the loss of biodiversity that is driving pandemics; ### deleted


### 212. highlights that in the face of the current geopolitics of globalisation , the eu should detect high-risk dependencies and establish production capacities for related products in the eu; asks for a single market emergency instrument to be established enabling the eu , in the event of a crisis , to act directly and coercively to protect the single market; ### deleted


### 212. highlights that in the face of the current geopolitics of globalisation , the eu should detect high-risk dependencies and establish production capacities for related products in the eu; asks for a single market emergency instrument to be established enabling the eu , in the event of a crisis , to act directly and coercively to protect the single market; ### 212. highlights that in the face of the current geopolitics of globalisation , the eu should detect high-risk dependencies and establish production capacities for related products in the eu; asks for a single market emergency instrument to be established enabling the eu , in the event of a crisis , to act directly to protect the single market;


### 213. underlines the need to shift to a more pragmatic trade policy and that targeted protectionist instruments can be appropriate tools to enhance the eu’s bargaining power , protect the eu’s fundamental interests and ultimately ensure that global supply chains are actually open to the eu; ### deleted


### 214. notes the close cooperation between the coalition for epidemic preparedness innovations (cepi) and the global alliance for vaccines and immunizations (gavi) , under the auspices of the who and unicef , leading to the creation of covax , which aimed to ensure that cepi’s funding led to vaccines that would be accessible to all; ### 214. notes the close cooperation between the coalition for epidemic preparedness innovations (cepi) and the global alliance for vaccines and immunizations (gavi) , under the auspices of the who and unicef , leading to the creation of covax , which aimed to ensure that cepi’s funding led to vaccines that would be accessible to all , while it ended up amounting to the promotion of generic treatments of limited and temporary efficacy , which failed to stop the spread of the sars-cov-2 virus , creating a false sense of security and thus facilitating the global spread of the pandemic;


### 214. notes the close cooperation between the coalition for epidemic preparedness innovations (cepi) and the global alliance for vaccines and immunizations (gavi) , under the auspices of the who and unicef , leading to the creation of covax , which aimed to ensure that cepi’s funding led to vaccines that would be accessible to all; ### 214. notes the close cooperation between the coalition for epidemic preparedness innovations (cepi) and the global alliance for vaccines and immunizations (gavi) , under the auspices of the who and unicef , leading to the creation of covax , which aimed to ensure that cepi’s funding led to vaccines that would be accessible to all; yet failed to deliver on this promise;


### 214. notes the close cooperation between the coalition for epidemic preparedness innovations (cepi) and the global alliance for vaccines and immunizations (gavi) , under the auspices of the who and unicef , leading to the creation of covax , which aimed to ensure that cepi’s funding led to vaccines that would be accessible to all; ### 214. notes the close cooperation between the coalition for epidemic preparedness innovations (cepi) and the global alliance for vaccines and immunizations (gavi) , under the auspices of the who and unicef , leading to the creation of covax , which aimed to ensure that cepi’s funding led to vaccines that would be accessible to all , yet failed to deliver on this promise;


### 215. notes that cepi used recoverable loans to secure doses on behalf of covax facilities; underlines the fact that while cepi had some contingency funding solutions it had to rely mostly on fundraising; ### 215. notes that cepi used recoverable loans to secure doses on behalf of covax facilities , without considering the vaccines’ safety and efficacy in providing protection from infection; underlines the fact that while cepi had some contingency funding solutions it had to rely mostly on fundraising;


### 216. welcomes the fact that equitable access to vaccines has been the top priority of global foundations , including cepi and gavi , and that cepi has been putting in practice the not-for-profit / no-loss principle for vaccines intended for low- and middle-income countries; ### 216. welcomes the fact that equitable access to vaccines has been the top priority of global foundations , including cepi and gavi , yet notes that cepi investments did not resulted in priority access to approved vaccines for covax , as only 1 of the 9 vaccine candidates in cepi’s portfolio ended up being supplied through covax in 2021;


### 216. welcomes the fact that equitable access to vaccines has been the top priority of global foundations , including cepi and gavi , and that cepi has been putting in practice the not-for-profit / no-loss principle for vaccines intended for low- and middle-income countries; ### 216. notes the fact that universal access to vaccines has been the top priority of global foundations , including cepi and gavi , and that cepi has been putting in practice the not-for-profit / no-loss principle for doses intended for low- and middle-income countries;


### 217. considers that while donation of doses is good , these donations have to be thoroughly planned to ensure they make an optimal contribution to the recipients’ vaccination strategies; ### 217. considers that while donation of doses may be appropriate in some cases , these donations need taken into account its needs , possibilities and requirements of the recipient country and have to be thoroughly planned to ensure they make an optimal contribution to the recipients’ vaccination strategies;


### 217. considers that while donation of doses is good , these donations have to be thoroughly planned to ensure they make an optimal contribution to the recipients’ vaccination strategies; ### 217. considers that while donation of doses is good , these donations need to take into account needs , possibilities and requirements of the recipient country and have to be thoroughly planned to ensure they make an optimal contribution to the recipients’ vaccination strategies;


### 217. considers that while donation of doses is good , these donations have to be thoroughly planned to ensure they make an optimal contribution to the recipients’ vaccination strategies; ### 217. considers that these donations should include careful monitoring of adverse effects on the population;


### 87. calls for the continuous professional development of healthcare workers and for protective measures for their physical and mental health , as well as vaccinations for them , to be ensured; ### 87. calls for the continuous professional development of healthcare workers and for protective measures for their physical and mental health to be ensured;


### 88. looks forwards to the inclusion of mental health in the eu health union; ### deleted


### 89. calls on the member states to properly finance their health systems in order to ensure their immediate and long-term resilience , and to invest in critical health infrastructure , tools , structures , processes and laboratory capacity; ### 89. calls on the member states to properly finance their health systems in order to ensure their immediate and long-term resilience , and to invest in critical health infrastructure , tools , structures , processes and laboratory capacity , at the same time guaranteeing maximum transparency and constantly monitoring the aforesaid structures to ensure they are being properly run;


### 89. calls on the member states to properly finance their health systems in order to ensure their immediate and long-term resilience , and to invest in critical health infrastructure , tools , structures , processes and laboratory capacity; ### 89. calls on the member states to properly finance their health systems in order to ensure their immediate and long-term resilience , and to invest in critical public health infrastructure , tools , structures , processes and laboratory capacity;


### 90. believes , considering that by nature pandemics are very unpredictable and with the benefit of hindsight , that lessons need to be learned on how to be better prepared for negotiations with companies in order to avoid ending up with surplus vaccines and medical countermeasures; ### 90. believes that lessons need to be learned on how to be better prepared for negotiations with companies in any future emergencies in order to avoid a repeat of the indefensible imbalance in the protection of the public interest against that of the private sector , by which considerable resources were taken away from areas of expenditure that were equally important , only to end up with vast quantities of surplus vaccines and medical countermeasures , with the resulting huge loss of revenue for the member states;


### 90. believes , considering that by nature pandemics are very unpredictable and with the benefit of hindsight , that lessons need to be learned on how to be better prepared for negotiations with companies in order to avoid ending up with surplus vaccines and medical countermeasures; ### 90. believes , considering that by nature pandemics are very unpredictable and with the benefit of hindsight , that lessons need to be learned from joint procurement initiatives on how to be better prepared for negotiations with companies in order to avoid ending up with delivery delays or surplus vaccines and medical countermeasures;


### 91. urges the improvement of common and joint procurement procedures in emergency situations and a more coordinated approach , allowing for contracts to be adapted; ### 91. urges the improvement of common and joint procurement procedures in emergency situations and a more coordinated approach , allowing for contracts to be adapted; calls on the commission and member states to ensure that advance purchases follow principles of fair pricing , transparency , ip sharing , and a fair return of public investment; stresses the need to ensure that manufacturers remain liable and fully responsible for compensating injured consumers economically;


### 91. urges the improvement of common and joint procurement procedures in emergency situations and a more coordinated approach , allowing for contracts to be adapted; ### 91. urges the improvement of potential common and joint procurement procedures in emergency situations and a more coordinated approach , allowing for contracts to be adapted and maximum transparency;


### 92. recommends that the eu establish adequate systems to provide manufacturers with proper at-risk funding during emergencies in order to quickly adapt and scale-up production , avoiding disruptions and shortages of medicines , medical devices and services; ### 92. recommends that the eu establish adequate systems to provide manufacturers with proper at-risk funding during emergencies in order to quickly adapt and scale-up production , avoiding disruptions and shortages;of health technologies , medical products and services; such mechanisms shall be transparent and contingent to approval and revision by legislative bodies;


### 92. recommends that the eu establish adequate systems to provide manufacturers with proper at-risk funding during emergencies in order to quickly adapt and scale-up production , avoiding disruptions and shortages of medicines , medical devices and services; ### 92. recommends that the eu establish adequate systems to provide manufacturers with proper at-risk funding during emergencies , on condition that intellectual property rights and profits related to products financed with public money be shared equitably , in order to quickly adapt , monitor and scale-up production , avoiding disruptions and shortages of medicines , medical devices and services;


### 93. calls on the commission to ensure that the revision of the general pharmaceutical legislation builds on a good understanding of the root causes of medicine shortages; highlights the need for the union’s pharmaceutical industry to have a diversified supply chain and a medicine-shortage risk-mitigation plan to cope with any vulnerabilities and risks to the supply chain; ### 93. calls on the commission to ensure that the revision of the general pharmaceutical legislation builds on a good understanding of the root causes of medicine shortages and puts the focus on preventative measures; highlights the need for the union’s pharmaceutical industry to have a diversified supply chain and a medicine-shortage risk mitigation plan to cope with any vulnerabilities and risks to the supply chain; stresses the importance of requiring pharmaceutical companies to have adequate levels of safety stocks and to provide early notice of medicine shortages;


### 94. highlights the valuable role of community pharmacies and recognises their key contribution during the pandemic in continuously providing an essential and quality service; suggests that pharmacists should play a more active role in epidemiology surveillance to contribute monitoring the insurgence of cds , and invites the member states to include them in their health , care and research programmes; calls for greater recognition of pharmacies in rural areas , which enable such areas to retain their populations and ensure the availability of medicines; ### 94. highlights the valuable role of community pharmacies and recognises their key contribution during the pandemic in continuously providing an essential and quality service; suggests that pharmacists should play a more active role in proper epidemiology surveillance to contribute monitoring the insurgence of cds , and invites the member states to include them in their health , care and research programmes; calls for greater recognition of pharmacies in rural areas , which ensure the availability of medicines;


### 95. proposes that global supply chains be opened to the eu in order to prevent tariff retaliation and that stronger provisions be promoted within contracts , especially related to supply disruptions; calls for the detection of high-risk dependencies and the establishment of production capacities of related products in the eu; ### 95. proposes that stronger provisions be promoted within contracts , especially related to supply disruptions; calls for the detection of high-risk dependencies and the establishment of production capacities of related products in the eu; stresses the need to organize public and non-profit production of medicines;


### 95. proposes that global supply chains be opened to the eu in order to prevent tariff retaliation and that stronger provisions be promoted within contracts , especially related to supply disruptions; calls for the detection of high-risk dependencies and the establishment of production capacities of related products in the eu; ### 95. proposes that stronger provisions be promoted within contracts , especially related to supply disruptions; calls for the detection of high-risk dependencies and the establishment of production capacities of related products in the eu; stresses the need to facilitate non-profit production of medicines;


### 96. believes that the eu should reduce its dependence on unreliable trade partners and act decisively to prevent drug shortages; advises mapping out supply chain vulnerabilities related to the european system of sourcing medical products and active pharmaceutical ingredients from outside europe; ### 96. believes that the eu should , as far as possible , reduce its dependence on non-european trade partners and act decisively to prevent drug shortages; advises mapping out supply chain vulnerabilities related to the european system of sourcing medical products and active pharmaceutical ingredients from outside europe;


### 97. believes that the eu should ensure better sharing of data from the industry , earlier projections on where shortages may occur in the future and greater transparency in the production and distribution chain of medicinal products where this would promote the availability and accessibility of medicines without infringing on business sensitive information; ### 97. believes that the eu should ensure better and more precise sharing of data from the industry , earlier projections on where shortages may occur in the future and greater transparency in the production and distribution chain of medicinal products;


### 97. believes that the eu should ensure better sharing of data from the industry , earlier projections on where shortages may occur in the future and greater transparency in the production and distribution chain of medicinal products where this would promote the availability and accessibility of medicines without infringing on business sensitive information; ### 97. believes that the eu should ensure better sharing of data from the industry , earlier projections on where shortages may occur in the future and greater transparency in the production and distribution chain of medicinal products where this would promote the availability and accessibility of medicines;


### 97. believes that the eu should ensure better sharing of data from the industry , earlier projections on where shortages may occur in the future and greater transparency in the production and distribution chain of medicinal products where this would promote the availability and accessibility of medicines without infringing on business sensitive information; ### 97. believes that the eu should ensure better sharing of data from the industry , earlier projections on where shortages may occur in the future and greater transparency in the production and distribution chain of medicinal products where this would promote the availability and accessibility of medicines prioritising public interest;


### 99. calls on the commission to promote dialogue with the member states and all relevant stakeholders to promote ‘made in europe’ pharmaceuticals by strengthening manufacturing and supply resilience and by assessing additional criteria for national pricing at no additional cost to patients and without prejudice to the sustainability of the health system; stresses that these criteria should include high environmental manufacturing standards , robust supply chain management and investment in innovation and research; believes that stimulating and building on an attractive european industrial ecosystem for the pharmaceutical sector is one of the key conditions for continuing to foster the relocation of production facilities back to the eu; believes further that relocations of this kind can help to make eu healthcare systems more independent from third countries and more resilient to disruptions; ### 99. calls on the commission to promote dialogue with the member states and all relevant stakeholders to promote ‘made in europe’ pharmaceuticals by strengthening manufacturing and supply resilience and by assessing additional criteria for national pricing at no additional cost to patients and without prejudice to the sustainability of the health system; stresses that these criteria should include high environmental manufacturing standards , robust supply chain management and demonstrable investment in innovation and research; believes that stimulating and building on an attractive european industrial ecosystem for the pharmaceutical sector is one of the key conditions for continuing to foster the relocation of production facilities back to the eu; believes further that relocations of this kind can help to make eu healthcare systems more independent from third countries and more resilient to disruptions; expresses concern that such efforts could increase prices of medical tools in the eu and globally;


### 99. calls on the commission to promote dialogue with the member states and all relevant stakeholders to promote ‘made in europe’ pharmaceuticals by strengthening manufacturing and supply resilience and by assessing additional criteria for national pricing at no additional cost to patients and without prejudice to the sustainability of the health system; stresses that these criteria should include high environmental manufacturing standards , robust supply chain management and investment in innovation and research; believes that stimulating and building on an attractive european industrial ecosystem for the pharmaceutical sector is one of the key conditions for continuing to foster the relocation of production facilities back to the eu; believes further that relocations of this kind can help to make eu healthcare systems more independent from third countries and more resilient to disruptions; ### 99. calls on the commission to promote dialogue with the member states and all relevant stakeholders to promote ‘made in europe’ pharmaceuticals by strengthening manufacturing and supply resilience and by assessing additional criteria for national pricing at no additional cost to patients and without prejudice to the sustainability of the health system; stresses that these criteria should include high bioethical , transparency and environmental manufacturing standards , robust and transparent supply chain management and investment in innovation and research; believes that stimulating and building on a stable and secure european industrial ecosystem for the pharmaceutical sector is one of the key conditions for continuing to foster the relocation of production facilities back to the eu; believes further that relocations of this kind can help to make eu healthcare systems more independent from third countries and more resilient to disruptions;


### 100. recommends the simplification and harmonisation of regulatory procedures for the approval of vaccines and medicines in order to improve the fluidity of global supply chains; ### deleted


### 100. recommends the simplification and harmonisation of regulatory procedures for the approval of vaccines and medicines in order to improve the fluidity of global supply chains; ### 100. recommends the simplification and harmonisation of regulatory procedures without sacrificing safety and quality controls for the approval of vaccines and medicines in order to improve the fluidity of global supply chains;


### 101. suggests developing networks that can be mobilised to produce a variety of technologies at short notice (such as the eu fab) and address supply chain challenges and trade barriers that impact the production process; ### 101. suggests developing networks that can be mobilised to produce a variety of technologies at short notice (such as the eu fab) and address supply chain challenges and trade barriers that impact the production process; stresses the need to facilitate non-profit production of medicines;


### 101. suggests developing networks that can be mobilised to produce a variety of technologies at short notice (such as the eu fab) and address supply chain challenges and trade barriers that impact the production process; ### 101. suggests developing networks that can be mobilised to produce a variety of technologies at short notice (such as the eu fab) and address supply chain challenges and trade barriers that impact the production and distribution processes;


### 102. encourages further investment in r&d , by increasing the resources of the eu framework programme for research and innovation and the eu4health programme , and establishing hera as a future eu agency supporting research to make vaccines available in times of crisis; ### 102. encourages further investment in r&d , by streamlining and better use resources of the horizon europe and imi and the eu4health programme , and hera , as a future eu agency supporting research to make vaccines and other strategic health technologies available in times of crisis; to address unmet health needs and by leveraging such public investments to ensure more affordable and better accessible end-products;


### 102. encourages further investment in r&d , by increasing the resources of the eu framework programme for research and innovation and the eu4health programme , and establishing hera as a future eu agency supporting research to make vaccines available in times of crisis; ### 102. encourages further investment in r&d , by the streamline and better use of the resources of horizon europe and imi and the eu4health programme , and hera as a future eu agency supporting research to make vaccines available in times of crisis; calls for the creation of a european medicines infrastructure for pharmaceutical r&d in the public interest , with a public-driven r&d agenda and laboratory capacity;


### 102. encourages further investment in r&d , by increasing the resources of the eu framework programme for research and innovation and the eu4health programme , and establishing hera as a future eu agency supporting research to make vaccines available in times of crisis; ### 102. encourages further investment in r&d , under conditions that guarantee a return on investment for the public sector , by increasing the resources of the eu framework programme for research and innovation;


### 103. calls for more research to determine the underlying causes , frequency , and best treatment options for long covid and post-acute covid-19 syndrome , since these conditions are still not fully understood; calls therefore for a coordinated programme of surveillance systems that includes data from each member state , using consistent case definitions and methodologies , and encompassing the impact of this condition on health , employment , and the economy; ### 103. calls for more research to determine the underlying causes , frequency , and best treatment options for the adverse effects of the covid vaccines , since these effects are occurring ever more frequently , often with very serious outcomes , and they are still not adequately monitored , logged or fully understood; calls therefore for the data collected by european , national and eu surveillance systems to be shared with the international scientific community and for cross-cutting research to be promoted on these subjects , using consistent case definitions and methodologies , and encompassing the impact of these disorders on health , employment , and the economy; calls for the marketing authorisations for the covid vaccines to be suspended pending the outcome of this research and , if they are found to be a danger to health , for the authorisations to be immediately withdrawn;


### 104. calls on the commission to periodically evaluate and review the incentive system , increase price transparency , and highlight the factors limiting affordability and patient access to medicinal products; ### 104. calls on the commission to periodically evaluate and review the performance of incentive system , ensure net price transparency , and highlight the factors limiting affordability of health technologies and the economic sustainability of public health systems;


### 105. encourages responsible ways to enhance transparency regarding public vaccine funding and procurement , the real costs of r&d , and access to clinical trials results and related data through the clinical trial information system; ### 105. encourages responsible ways to ensure full transparency regarding public vaccine funding and procurement , the real costs of r&d , and access to clinical trials results and related data through the clinical trial information system;


### 105. encourages responsible ways to enhance transparency regarding public vaccine funding and procurement , the real costs of r&d , and access to clinical trials results and related data through the clinical trial information system; ### 105. encourages full transparency regarding public funding and procurement , the real costs of r&d , and access to clinical trials results and related data through the clinical trial information system;


### 105. encourages responsible ways to enhance transparency regarding public vaccine funding and procurement , the real costs of r&d , and access to clinical trials results and related data through the clinical trial information system; ### 105. encourages responsible ways to enhance transparency regarding public funding and procurement , the real costs of r&d , and access to clinical trials results and related data through the clinical trial information system;


### 106. urges the commission , member states and manufacturers to communicate the potential side effects of vaccines better and to do so in a consistent and coordinated way so as to avoid vaccine hesitancy and misinformation; ### 106. urges the commission , member states and manufacturers to communicate the potential side effects of vaccines better and to do so in a consistent and coordinated way so as to avoid vaccine hesitancy and misinformation; stresses the importance of pharmacovigilance , mitigation measures to prevent adverse reactions , liability , and swift compensation in case of injury;


### 106. urges the commission , member states and manufacturers to communicate the potential side effects of vaccines better and to do so in a consistent and coordinated way so as to avoid vaccine hesitancy and misinformation; ### 106. urges the commission , member states and manufacturers to communicate the potential side effects of vaccines better and to do so in a consistent and coordinated way so as to avoid false or misleading information or propaganda about the administration of these pharmaceuticals;


### 107. calls for hera to be made an autonomous agency , with a strong and well-defined mandate from council and parliament (including a proper industrial role and mandate) , and a budget to fulfil its mandate and increase resources; calls for hera to have a role in safeguarding the public interest; ### deleted


### 107. calls for hera to be made an autonomous agency , with a strong and well-defined mandate from council and parliament (including a proper industrial role and mandate) , and a budget to fulfil its mandate and increase resources; calls for hera to have a role in safeguarding the public interest; ### 107. calls for hera to be made an autonomous agency , with a strong and well-defined mandate from council and parliament (including a proper industrial role and mandate) , and a budget to fulfil its mandate and increase resources; calls for hera to have a role in safeguarding the public interest including through access conditions and legal options to mandate technology transfer and knowledge sharing; calls for hera's governance to have much strengthened transparency and democratic accountability;


### 109. is concerned that during the pandemic the executive branch had the upper hand in emergency decision-making , which undermined the role of the european parliament; calls on the commission and the council to refrain from using article 122 tfeu , and to increase parliamentary control and codecision for various instruments so as to bolster the legitimacy of emergency response actions; ### 109. is concerned that during the pandemic the executive branch had the upper hand in emergency decision-making , which undermined the role of the european parliament and rode roughshod over the democratic principles of the legislative processes; calls on the commission and the council to refrain from using article 122 tfeu , and to increase parliamentary control and codecision for various instruments so as to bolster the legitimacy of emergency response actions;


### 109. is concerned that during the pandemic the executive branch had the upper hand in emergency decision-making , which undermined the role of the european parliament; calls on the commission and the council to refrain from using article 122 tfeu , and to increase parliamentary control and codecision for various instruments so as to bolster the legitimacy of emergency response actions; ### 109. is concerned that during the pandemic the executive branch dominated emergency decision-making , which undermined the role of the european parliament; calls on the commission and the council to refrain from using article 122 tfeu , and to allow for increased parliamentary control and codecision for various instruments so as to bolster the legitimacy of emergency response actions;


### — having regard to the charter of fundamental rights of the european union , in particular to articles 31 , 32 , and 35 thereof , ### — having regard to the charter of fundamental rights of the european union , in particular to articles 10 , 11 , 14 , 15 , 21 , 24 , 31 , 32 and 35 thereof ,


### 1. acknowledges that the spread of the covid-19 has cost the lives of millions of people in europe and the world and has caused irreparable damage , and that the eu , as well as the rest of the world , was not ready to cope with this unprecedented health crisis and its shock waves , which have affected societies and economies worldwide; ### 1. acknowledges that the spread of the covid-19 has cost the lives of millions of people in europe and the world and has caused irreparable damage , and that the eu , as well as the rest of the world , was not ready to cope with this unprecedented health crisis and its shock waves , which have affected societies and economies worldwide , magnifying inequalities that risks growing to irreversible proportions;


### 1. acknowledges that the spread of the covid-19 has cost the lives of millions of people in europe and the world and has caused irreparable damage , and that the eu , as well as the rest of the world , was not ready to cope with this unprecedented health crisis and its shock waves , which have affected societies and economies worldwide; ### 1. acknowledges that the spread and the response prepared to covid-19 have cost the lives of millions of people in europe and the world and have caused irreparable damage , and that the eu , as well as the rest of the world , was not ready to cope with this unprecedented health crisis and its shock waves , which have affected societies and economies worldwide;


### 2. considers that , despite shortcomings and gaps in prevention , preparedness and response , the eu developed a common response to the pandemic and took actions to ensure the swift development and fair distribution of vaccines on the european continent and globally; ### 2. considers that , despite shortcomings and gaps in prevention , preparedness and response , the eu developed a common response to the pandemic and took actions to ensure the swift development of vaccines on the european continent; regrets that despite the public investment in r&d to develop vaccines , diagnostics and treatments to tackle the covid-19 pandemic , the eu and the member states failed to include any binding conditions to guarantee the availability , affordability , and accessibility of medical products to all those in need , including to low- and middle- income countries;


### 2. considers that , despite shortcomings and gaps in prevention , preparedness and response , the eu developed a common response to the pandemic and took actions to ensure the swift development and fair distribution of vaccines on the european continent and globally; ### 2. considers that , in addition to shortcomings and gaps in prevention , preparedness and response , the eu adopted a common response to the pandemic based almost exclusively on the swift development and the distribution of vaccines on the european continent and globally;


### 3. notes that the covid-19 pandemic acted as a catalyst to speed up transformations on the path to the digital and green transitions , and to pay deeper attention to health; ### deleted


### 4. highlights that the pandemic exacerbated existing structural issues in the health sector , in particular workforce shortages; ### 4. highlights that the pandemic exacerbated existing structural issues in the health sector , in particular workforce shortages and recognising that the avoidable deaths of so many people living in residential facilities will , for many families , be remembered as a defining characteristic of the pandemic. for too long , social care has been the poor relation of the health system. few governments have put in place systems to fund it adequately , despite clear warnings from demographers about ageing populations;


### 4. highlights that the pandemic exacerbated existing structural issues in the health sector , in particular workforce shortages; ### 4. highlights that the pandemic exacerbated existing structural issues in the health sector , in particular workforce shortages and global inequities in production , supply and access to live-saving medical products and health technologies;


### 4. highlights that the pandemic exacerbated existing structural issues in the health sector , in particular workforce shortages; ### 4. highlights that the pandemic exacerbated existing structural issues in the health sector , in particular workforce shortages; and global inequities in production , supply and access to live-saving medical products/ health technologies;


### 4. highlights that the pandemic exacerbated existing structural issues in the health sector , in particular workforce shortages; ### 4. highlights that the pandemic exacerbated existing structural problems in the health sector , in particular workforce shortages;


### 5. affirms the importance of preparedness and resilience in the face of crises , particularly in terms of healthcare systems and supplies , in increasing strategic autonomy in key areas , such as vaccine production and distribution; ### 5. affirms the importance of preparedness and resilience in the face of outbreaks and health emergencies , particularly in terms of healthcare systems and supplies , in increasing strategic autonomy and global diversity/ diversification of production in key areas , such as vaccine and medicine production and supply;


### 5. affirms the importance of preparedness and resilience in the face of crises , particularly in terms of healthcare systems and supplies , in increasing strategic autonomy in key areas , such as vaccine production and distribution; ### 5. affirms the importance of preparedness and resilience in the face of crises , particularly in terms of healthcare systems and services , including better work conditions for health workers and supplies , in increasing strategic autonomy in key areas , such as vaccine production and distribution;


### 5. affirms the importance of preparedness and resilience in the face of crises , particularly in terms of healthcare systems and supplies , in increasing strategic autonomy in key areas , such as vaccine production and distribution; ### 5. affirms the importance of preparedness and transparency in public healthcare management in the face of crises , particularly in terms of prevention strategies , holistic treatments and healthcare supplies , in increasing strategic autonomy in key areas;


### 8. emphasises that the economy supports our welfare state , personal freedom and a good future; calls for the eu to strengthen its economic performance in hard times by coupling economic and social measures; ### deleted


### 9. highlights that the pandemic has increased inequalities between countries and within countries , that life expectancy in europe has dropped for the first time in 50 years and that the future of the universal coverage and social welfare model has been jeopardised; ### 9. highlights that the pandemic has increased inequalities between countries and within countries , that life expectancy in europe has dropped for the first time in 50 years , that the future of the universal health coverage (uhc) and social welfare model being jeopardised is also the product of several years of austerity measures in health , low salaries and the underfunding of social security in a capitalist model economy;


### 10. observes that the medical emergency affected security and stability conditions and social relationships , changed ways of work and education , impacted various societal groups and increased global inequalities; ### 10. observes that the medical emergency allowed the adoption of measures that affected security and stability conditions and social relationships , changed ways of work and education , impacted various societal groups and increased global inequalities and discrimination;


### 11. emphasises the importance of learning lessons and being better prepared for future crises and stresses that a high level of human health protection must be ensured in the definition and implementation of all union policies and activities; stresses that we are still learning about the effects of covid on health and health systems , in particular the impact of so-called long covid effects; ### 11. emphasises the importance of learning lessons and being better prepared for future crises and stresses that a high level of human health protection , transparency and propriety in public and private healthcare management , together with respect for all the fundamental rights of the individual , must be ensured in the definition and implementation of all union policies and activities; stresses that we are still learning about the effects of covid and of covid vaccines on health and health systems , in particular the impact of so-called long covid effects and long-term damage by mrna therapies;


### 11. emphasises the importance of learning lessons and being better prepared for future crises and stresses that a high level of human health protection must be ensured in the definition and implementation of all union policies and activities; stresses that we are still learning about the effects of covid on health and health systems , in particular the impact of so-called long covid effects; ### 11. emphasises the importance of learning lessons and being better prepared for future crises and stresses that a high level of human health protection must be ensured in the definition and implementation of all union policies and activities; stresses that we are still learning about the effects of covid on health and health systems and services , in particular the impact of so-called long covid effects;


### 11. emphasises the importance of learning lessons and being better prepared for future crises and stresses that a high level of human health protection must be ensured in the definition and implementation of all union policies and activities; stresses that we are still learning about the effects of covid on health and health systems , in particular the impact of so-called long covid effects; ### 11. emphasises the importance of learning lessons and being better prepared for future crises and stresses that the highest level of human health protection must be ensured in the design , definition and implementation of all union policies , legislations and activities; stresses that we are still learning about the effects of covid on health and health systems , in particular the impact of long covid;


### 12. stresses that europe can only pull through future pandemics if the european family stands together in solidarity and responsibility , and fully utilises its capabilities to coordinate better and deliver the needed added-value to eu governments and their citizens; ### 12. believes that presenting the possibility or even more the probability of forthcoming future pandemics is scientifically a baseless gamble , and that instead we need to reclaim the value of proper early home treatments for the regular seasonal influenza outbreaks that occur each year;


### 13. underlines the importance of science-based decision-making and consistent communication with citizens from all the stakeholders involved , including eu and member state public institutions , the scientific community , the private sector and civil society organisations; ### 13. underlines the importance of independent evidence-based and science-based decision-making and transparent communication with citizens , that allows dialectic discussion of the available data and impartial scientific debate between differing positions , with the involvement of all the stakeholders , including eu and member state public institutions , the scientific community , the private sector and civil society;


### 13. underlines the importance of science-based decision-making and consistent communication with citizens from all the stakeholders involved , including eu and member state public institutions , the scientific community , the private sector and civil society organisations; ### 13. underlines the importance of public health-led , evidence-based and scientifically sound decision-making and consistent communication with citizens from all the stakeholders involved , including eu and member state public institutions , the scientific community , the private sector and civil society organisations;


### 13. underlines the importance of science-based decision-making and consistent communication with citizens from all the stakeholders involved , including eu and member state public institutions , the scientific community , the private sector and civil society organisations; ### 13. underlines the importance of evidence -based and scientifically sound decision-making and consistent communication with citizens from all the stakeholders involved , including eu institutions and member state public offices , the scientific community , the private sector and civil society organisations;


### 14. calls for the eu to continue on the path towards establishing a european health union that brings true added-value to the health governance of the member states and operates in fields that cannot be covered by the member states alone; ### deleted


### 15. recognises that all the actions taken during the pandemic were meant to safeguard the right to health and life , but that some actions nevertheless implied the existence of limitations on other fundamental rights; highlights that , because the crisis was unprecedented , governments had to take swift action with very little preparation and a lack of internal expertise; ### 15. recognises that many actions taken during the pandemic implied the existence of limitations on fundamental rights; highlights that the fact that governments had to take swift action with very little preparation and a lack of internal expertise does not justify violation of the principles and rights enshrined in the european charter of fundamental rights;


### 15. recognises that all the actions taken during the pandemic were meant to safeguard the right to health and life , but that some actions nevertheless implied the existence of limitations on other fundamental rights; highlights that , because the crisis was unprecedented , governments had to take swift action with very little preparation and a lack of internal expertise; ### 15. recognises that all the actions taken during the pandemic were meant to safeguard the right to health and life , but that some actions nevertheless required the limitations on other fundamental rights; highlights that , because the crisis was unprecedented , governments had to take swift action with very little preparation and a lack policy alternatives;